Skip to main navigation Skip to search Skip to main content

Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective

  • Srujitha Marupuru
  • , Daniel Arku
  • , David R. Axon
  • , Lorenzo Villa-Zapata
  • , Mohsen Yaghoubi
  • , Marion K. Slack
  • , Terri Warholak
  • The University of Arizona
  • Mercer University College of Health Professions

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)831-841
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume23
Issue number7
DOIs
StatePublished - 2023

ASJC Scopus Subject Areas

  • Health Policy
  • Pharmacology (medical)

Keywords

  • cost-effectiveness
  • gastric cancer
  • metastatic
  • nivolumab
  • trial

Cite this